NasdaqGS:DVAXBiotechs
Should Dynavax Technologies' (DVAX) $100 Million Buyback and Guidance Update Prompt a Reassessment by Investors?
Dynavax Technologies Corporation recently announced a US$100 million share repurchase program, reported its third quarter 2025 earnings, and reiterated full-year net product revenue guidance for HEPLISAV-B of US$315 million to US$325 million.
This series of updates highlights both management’s ongoing confidence in the core hepatitis B franchise and a renewed emphasis on capital returns to shareholders.
Let’s explore how the newly announced share repurchase program may influence Dynavax's...